Stock Market Reviews

NMRA (Neumora Therapeutics, Inc.) News

Get the latest news, insights, and market updates on NMRA (Neumora Therapeutics, Inc.). Explore the news page 3 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Neumora Therapeutics to Participate in Upcoming Conferences in September
  WATERTOWN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven programs that target novel mechanisms of action for a broad range of underserved, prevalent diseases, today announced that the Company will participate in three investor conferences in September. 2025 Wells Fargo Healthcare Conference: Members of management will be available for one-on-one meetings on Thursday,
  Sep 2, 2025 - $NMRA
• Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861
  Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the best IPO stocks to buy according to Wall Street analysts. Earlier on July 9, Neumora Therapeutics initiated a Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study for its drug candidate, called NMRA-861. The study is being conducted in healthy adult participants and adults with stable schizophrenia. In preclinical […]
  Aug 20, 2025 - $NMRA
• Black Diamond Therapeutics And 2 Promising Penny Stocks For Savvy Investors
  As the major U.S. stock indices hover near record highs following two consecutive weeks of gains, investors are closely monitoring economic indicators and corporate earnings for signs of market direction. In this context, penny stocks—often representing smaller or emerging companies—can present unique opportunities for those seeking value and growth potential outside the mainstream market. Though traditionally seen as speculative, these stocks may offer promising prospects when backed by...
  Aug 18, 2025 - $NMRA
• Elevidys sales weaken; Neumora gets into obesity
  Sarepta reported a quarter-on-quarter dip in sales for its Duchenne gene therapy. Elsewhere, Jazz won FDA approval of a brain cancer drug and Novo decided to advance a Prothena medicine into Phase 3.
  Aug 8, 2025 - $NMRA
• Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
  Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor, with data from diet-induced obesity (DIO) mouse model expected in 2025 Entering catalyst-rich period with up to six clinical data readouts in patients over the next 18 months, including Phase 3 data for nava
  Aug 6, 2025 - $NMRA
• Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating
  Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the 11 Best New Penny Stocks to Buy Right Now. On July 16, Mizuho increased its price target for Neumora Therapeutics, Inc. (NASDAQ:NMRA) from $4 to $5 and kept an “Outperform” rating. This decision came after Neumora Therapeutics, Inc. (NASDAQ:NMRA) introduced NMRA-861, which is a strong and selective […]
  Jul 29, 2025 - $NMRA
• Neumora Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025
  WATERTOWN, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven brain disease programs including three clinical-stage programs, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, August 6, 2025 to report its second quarter 2025 financial results and provide a business update. A live webcast of the event will be available on the
  Jul 23, 2025 - $NMRA
• Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating
  Neumora Therapeutics, Inc. (NASDAQ:NMRA) is one of the hot penny stocks to invest in now. On July 16, Mizuho analyst Graig Suvannavejh raised the firm’s price target on Neumora Therapeutics, Inc. (NASDAQ:NMRA) to $5 from $4, maintaining an Outperform rating on the shares. The rating update came after the introduction of NMRA-861 on July 9, when […]
  Jul 20, 2025 - $NMRA